Text Size

Characteristics and Prevalence of Tuberculosis and HIV in Masiphumelele Township, Cape Town, South Africa

This study has been completed.
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
Comprehensive International Program of Research on AIDS
Information provided by:
CIPRA SA
ClinicalTrials.gov Identifier:
NCT00346476
First received: June 28, 2006
Last updated: February 9, 2011
Last verified: February 2011
History of Changes
Results First Received: January 14, 2011  
Study Type: Observational
Study Design: Observational Model: Ecologic or Community;   Time Perspective: Prospective
Conditions: HIV Infections
Tuberculosis

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Participants Individuals in the Masiphumelele Township of Cape Town, South Africa, who have been potentially exposed to TB and/or HIV

Participant Flow:   Overall Study
    Participants  
STARTED     1250  
COMPLETED     1250  
NOT COMPLETED     0  



  Baseline Characteristics
  Show Baseline Characteristics


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Microbiologically Confirmed Tuberculosis Infection   [ Time Frame: At Year 5 ]
  Show Outcome Measure 1

2.  Primary:   Number of Participants With HIV Infection   [ Time Frame: At Year 5 ]
  Show Outcome Measure 2

3.  Secondary:   Changes in Clustering and Transmission of TB Among HIV Infected and Uninfected Participants   [ Time Frame: Year 1 to Year 5 ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

4.  Secondary:   Changes in the Clustering and Transmission of TB Among HIV Infected and Uninfected Participants After the Introduction of HAART   [ Time Frame: Year 1 to Year 5 ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

5.  Secondary:   Diversity of TB Strains Among HIV Infected Participants Receiving HAART, HIV Infected Participants Not Receiving HAART, and HIV Uninfected Participants   [ Time Frame: Year 1 to Year 5 ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

6.  Secondary:   Number of Recurrent Cases of TB Attributable to Endogenous Reactivation Versus Exogenous Re-infection in Both HIV Infected and Uninfected Participants   [ Time Frame: At Year 5 ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Prof LG Bekker
Organization: Desmond Tutu HIV Centre
phone: +27216506966
e-mail: Linda-Gail.Bekker@hiv-research.org.za


Publications:


Responsible Party: James McIntyre, CIPRA SA
ClinicalTrials.gov Identifier: NCT00346476     History of Changes
Other Study ID Numbers: CIPRA-SA Project 3B, U19AI053217
Study First Received: June 28, 2006
Results First Received: January 14, 2011
Last Updated: February 9, 2011
Health Authority: United States: Federal Government